LAG3 and cancer: However, despite the success of immune blockade therapies in various cancers, only a small subset of patients benefit from these strategies, necessitating continuous research efforts to identify additional targets––including V-domain Ig-containing suppressor of T cell activation (VISTA) [39], BTLA [40], and lymphocyte activation gene 3 (LAG3)––and develop new immune-blockade therapies.